IDDI announces the Appointment of a New Chief Commercial Officer


Louvain-la-Neuve, Belgium, May 13, 2019  – International Drug Development Institute (IDDI), a leading, therapy-focused Biostatistics and eClinical Services corporation based in Belgium with offices in Boston (MA), Raleigh (NC) and San Francisco (CA) announces the appointment of Serge Bodart as Chief Commercial Officer.

Serge brings a remarkable industry knowledge and experience to IDDI. In 2000, he co-founded Symfo, a Belgian company that pioneered the electronic collection of Patient Reported Outcomes (PRO). After he sold his business in 2012, he acted as the global electronic Clinical Outcome Assessment (eCOA) Subject Matter Expert at Biomedical Systems and led the company’s Sales and Marketing efforts. He later joined Bracket – a clinical trial technology and specialty services provider as a Senior Advisor for Outcomes Science with a worldwide sales, marketing and account management focus.

Prior to his career in the clinical trials industry, Serge graduated from the polytechnic division of the Belgian Royal Military Academy where he earned his Masters of Science in Telecommunications and served as a Major and helicopter pilot for over 20 years in the Belgian Army Aviation.

Speaking on the appointment, IDDI’s CEO, Damien Tremolet, said: “We are delighted to welcome Serge Bodart to IDDI. Serge brings an impressive and solid experience in clinical research, an unparalleled enthusiasm and energy that will help us continue to strengthen our unique offering of advanced biostatistics and innovative integrated eClinical Services among our Customers in the USA and Europe. His leadership will be a strong asset for IDDI moving forward.”

Serge will be responsible for the global commercial growth strategy of the company, for forging clients relationships, identifying their needs and ensuring we deliver the appropriate solutions.

About IDDI:

International Drug Development Institute (IDDI) is an expert organization in biostatistical and integrated eClinical services that is committed to assisting pharmaceutical, biotech, medical devices, nutrition and Academic  Companies in several disease areas, including oncology and ophthalmology. IDDI optimises the clinical development of drugs, biologics and devices thanks to proven statistical expertise and operational excellence. Founded in 1991, IDDI has offices in Belgium, Boston (MA), Raleigh (NC) and San Francisco (CA).